Akash Mukherjee

Researcher

University of Arkansas for Medical Sciences

faculty

9 h-index 69 pubs 245 cited

Research Areas

Acute Lymphoblastic Leukemia research CAR-T cell therapy research Immune Response and Inflammation Gut microbiota and health Cancer Treatment and Pharmacology Health and Medical Research Impacts Meta-analysis and systematic reviews

Links

ORCID Research Group

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Akash Mukherjee's research focuses on hematologic malignancies, particularly acute lymphoblastic leukemia (ALL), and related therapeutic interventions. He has investigated outcomes associated with brexucabtagene autoleucel, a CAR T-cell therapy, in adults with relapsed/refractory B-cell ALL, examining its efficacy as a standard of care and the impact of prior treatments. His work also explores immune effector cell-associated HLH-like syndrome and the role of gut microbiota, such as Bacteroides ovatus, in mitigating graft-versus-host disease. Mukherjee has co-authored numerous publications in this field and collaborates with researchers at the University of Arkansas for Medical Sciences, including Muthu Veeraputhiran, Ankur Varma, Mamatha Gaddam, and Manojna Konda. His scholarly contributions are reflected in an h-index of 9 and over 245 citations across 69 publications.

Metrics

  • h-index: 9
  • Publications: 69
  • Citations: 245

Selected Publications

  • The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (2025) DOI
  • Gut Microbiome Diversity and Composition Changes Post Allogeneic Hematopoietic Stem Cell Transplant (AlloSCT): A Single-Center Prospective Analysis (2024) DOI
  • The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2024) DOI
  • Assessment of Central Nervous System Responses in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Brexucabtagene Autoleucel As an FDA-Approved Standard of Care (2024) DOI
  • Real World Outcomes for AYA Patients with Relapsed/Refractory B-Cell ALL Receiving CD19-Directed CAR T-Cell Therapy (2024) DOI
  • Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) (2023) DOI
  • Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) (2023) DOI
  • The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2023) DOI
  • Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study (2023) DOI
  • Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) (2023) DOI
  • The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) (2023) DOI
  • Interdigitating Dendritic Cell Sarcoma and Indeterminate Dendritic Cell Tumor: Patient Characteristics, Prognostic Factors, and Survival Outcomes for Rare Dendritic Cell Neoplasms (2023) DOI
  • Immune Effector Cell-Associated HLH-like Syndrome: A Review of the Literature of an Increasingly Recognized Entity (2023) DOI
  • Epidemiology of Aggressive NK-Cell Leukemia in the United States: A SEER Population-Based Study (2021) DOI
  • Clinical Outcome of Refractory Lymphoma Patients with Non Response to Chimeric Antigen Receptor T Cell Therapy (2021) DOI

Collaborators

Researchers in the database who share publications

Muthu Veeraputhiran University of Arkansas for Medical Sciences 15 shared publications Ankur Varma University of Arkansas for Medical Sciences 5 shared publications Mamatha Gaddam University of Arkansas for Medical Sciences 2 shared publications Manojna Konda University of Arkansas for Medical Sciences 2 shared publications Michael R. Bishop University of Arkansas for Medical Sciences 2 shared publications Jim Zhongning Chen University of Arkansas for Medical Sciences 1 shared publication Alan Baltz University of Arkansas for Medical Sciences 1 shared publication Michael Scott Robeson University of Arkansas for Medical Sciences 1 shared publication

Similar Researchers

Based on overlapping research topics

Muthu Veeraputhiran University of Arkansas for Medical Sciences
Acute Lymphoblastic Leukemia research CAR-T cell therapy research Immune Response and Inflammation
Good match 5 shared topics
Alan Baltz University of Arkansas for Medical Sciences
CAR-T cell therapy research Immune Response and Inflammation Cancer Treatment and Pharmacology
Good match 5 shared topics
Wei Li University of Arkansas for Medical Sciences
Immune Response and Inflammation Gut microbiota and health Cancer Treatment and Pharmacology
Good match 5 shared topics
A. G. P. Brown University of Arkansas for Medical Sciences
Immune Response and Inflammation Cancer Treatment and Pharmacology Health and Medical Research Impacts
Good match 4 shared topics
Yifan Zhang National Center for Toxicological Research
Immune Response and Inflammation Gut microbiota and health Cancer Treatment and Pharmacology
Good match 4 shared topics
Mamatha Gaddam University of Arkansas for Medical Sciences
CAR-T cell therapy research Immune Response and Inflammation Cancer Treatment and Pharmacology
Good match 4 shared topics